Octreotide effect on hypersecretion of growth hormone in a patient with fibrous dysplasia: a case report.
We report the case of a 17-year-old adolescent boy with polyostotic fibrous dysplasia and hypersecretion of growth hormone (GH). The fasting serum GH, insulin-like growth factor-I (IGF-I), alkaline phosphatase activity and osteocalcin levels were all elevated. The GH secretion was stimulated by thyrotropin-releasing hormone and was not suppressed by an oral glucose test. Magnetic resonance imaging of the sella turcica showed no abnormal findings. The patient was treated with octreotide, 100 micrograms subcutaneous injection three times a day for two weeks to observe the effects of octreotide on growth hormone secretion. GH and IGF-I secretions were suppressed by octreotide therapy, while alkaline phosphatase activity and osteocalcin secretion were partially suppressed. We suggest that the high bone turnover states in this patient may be attributed to both hypersecretion of growth hormone and the polyostotic fibrous dysplasia itself.
Chen
H S
HS
Division of Endocrinology and Metabolism, Veterans General Hospital-Taipei, Taiwan, ROC.
Hwu
C M
CM
Shih
K C
KC
Kwok
C F
CF
Ho
L T
LT
D000293:Adolescent; D005359:Fibrous Dysplasia, Polyostotic / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D015675:Osteocalcin / Q000097:blood
D015675:Osteocalcin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D015282:Octreotide